SUMMARY
There are no therapies that reverse the proteotoxic misfolding events that underpin fatal neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and Parkinson's disease (PD). Hsp104, a conserved hexameric AAA+ protein from yeast, solubilizes disordered aggregates and amyloid but has no metazoan homolog and only limited activity against human neurodegenerative disease proteins. Here, we reprogram Hsp104 to rescue TDP-43, FUS, and a-synuclein proteotoxicity by mutating single residues in helix 1, 2, or 3 of the middle domain or the small domain of nucleotide-binding domain 1. Potentiated Hsp104 variants enhance aggregate dissolution, restore proper protein localization, suppress proteotoxicity, and in a C. elegans PD model attenuate dopaminergic neurodegeneration. Potentiating mutations reconfigure how Hsp104 subunits collaborate, desensitize Hsp104 to inhibition, obviate any requirement for Hsp70, and enhance ATPase, translocation, and unfoldase activity. Our work establishes that disease-associated aggregates and amyloid are tractable targets and that enhanced disaggregases can restore proteostasis and mitigate neurodegeneration.
INTRODUCTION
Protein misfolding underpins several fatal neurodegenerative disorders, including amyotrophic lateral sclerosis (ALS) and Parkinson's disease (PD) (Cushman et al., 2010) . In PD, a-synuclein (a-syn) forms highly toxic prefibrillar oligomers and amyloid fibrils that accumulate in cytoplasmic Lewy bodies (Cushman et al., 2010) . In ALS, TDP-43 or FUS accumulate in cytoplasmic inclusions in degenerating motor neurons (Robberecht and Philips, 2013) . Unfortunately, treatments for these disorders are palliative and ineffective due to the apparent intractability of aggregated proteins. Effective therapies are urgently needed that eliminate the causative proteotoxic misfolded conformers via degradation or reactivation of the proteins to their native fold.
Inspiration can be drawn from nature, where amyloidogenesis and protein misfolding have been subjugated for adaptive modalities (Newby and Lindquist, 2013) . For example, beneficial yeast prions are tightly regulated by Hsp104, a hexameric AAA+ protein that rapidly deconstructs various amyloids and prefibrillar oligomers Lo Bianco et al., 2008; Newby and Lindquist, 2013) . Hsp104 also reactivates proteins from disordered aggregates after environmental stress (Shorter, 2008) . Hsp104 is highly conserved in eubacteria and eukaryotes, except in metazoa, which bafflingly lack an Hsp104 homolog and display limited ability to disaggregate disordered and amyloid aggregates (Duennwald et al., 2012; Shorter, 2008 Shorter, , 2011 . Thus, Hsp104 could be harnessed to augment human proteostasis and counter protein misfolding in neurodegenerative disease (Shorter, 2008) . Indeed, Hsp104 synergizes with human Hsp70 and Hsp40 to resolve various misfolded species linked with human neurodegenerative disease and can partially antagonize protein misfolding and neurodegeneration in metazoa (Cushman-Nick et al., 2013; Duennwald et al., 2012; Lo Bianco et al., 2008; Shorter, 2011; Vacher et al., 2005) . Hsp70 overexpression can also mitigate neurodegeneration (Cushman-Nick et al., 2013) . However, these potentially therapeutic activities remain limited and vast improvements are needed to maximize therapeutic potential. Indeed, very high concentrations of Hsp104 are needed to antagonize human neurodegenerative disease proteins, which Hsp104 never ordinarily encounters, and some substrates are refractory to Hsp104 (DeSantis et al., 2012; Lo Bianco et al., 2008) .
A key but elusive goal is to engineer or evolve optimized chaperones against neurodegenerative disease substrates to maximize therapeutic efficacy (Shorter, 2008) . Chaperones are impractical targets for protein engineering due to their typically large size, and protein disaggregases such as Hsp104 have poorly understood structures, making rational design challenging (Saibil, 2013) . Here, we broach this issue and isolate potentiated Hsp104 variants that eradicate TDP-43, FUS, and a-syn aggregates and potently suppress toxicity. We report several artificially engineered chaperones to optimize proteostasis and thwart neurodegeneration. We suggest that neuroprotection may be possible for diverse neurodegenerative diseases via subtle structural modifications of existing chaperones.
RESULTS
Substrate-Binding Tyrosines in Hsp104 Pore Loops Are Optimal for Disaggregation Hsp104 is adapted for disaggregation of the yeast proteome. We sought to engineer Hsp104 variants to disaggregate TDP-43, an RNA-binding protein with a prion-like domain (Cushman et al., 2010) , which has no yeast homolog and is not a natural Hsp104 substrate. A yeast model of TDP-43 proteinopathies has been developed in which TDP-43 is overexpressed via a galactose-inducible promoter (Johnson et al., 2008) . TDP-43 aggregates in the cytoplasm and is toxic to yeast, which phenocopies TDP-43 pathology in disease and has enabled identification of common ALS genetic risk factors (Elden et al., 2010) . To explore Hsp104 sequence space against TDP-43 toxicity, we employed Dhsp104 yeast to assess Hsp104 variants in the absence of wild-type (WT) Hsp104. TDP-43 is highly toxic in Dhsp104 yeast and Hsp104
WT provides minimal rescue of toxicity (Johnson et al., 2008) . Thus, Dhsp104 yeast provide a platform to isolate more active Hsp104 variants. Each Hsp104 monomer contains two nucleotide-binding domains (NBD1 and NBD2) as well as an N-terminal, middle, and C-terminal domain . Hsp104 forms ring-shaped hexamers with a central pore through which substrate is threaded. To alter substrate specificity, we assessed Hsp104 variants bearing mutations in Hsp104's two substrate-binding pore loops . We mutated the conserved pore loop residues, Y257 and Y662, which mediate substrate binding and translocation (Tessarz et al., 2008) to all amino acids and screened this library of 400 variants for rescue of TDP-43 toxicity. After several rounds of selection, nearly all the variants possessed Y at one or more often both pore-loop positions. None of the pore-loop Hsp104 variants were more active than Hsp104
WT in rescuing TDP-43 toxicity. Thus, Y257 and Y662 are likely optimal for disaggregation.
Select Missense Mutations in the Middle Domain Potentiate Hsp104 Activity Next, we explored the coiled-coil middle domain (MD) of Hsp104, which is less conserved than the substrate-binding pore loops. MD variants can have unexpected gain-of-function phenotypes (Schirmer et al., 2004) . The Hsp104 MD (residues 411-538; Figure 1A ) facilitates optimal ATPase activity, communication between NBD1 and NBD2, intrinsic disaggregase activity, and interactions with Hsp70 during disordered aggregate dissolution (DeSantis and Shorter, 2012). We randomly mutagenized the MD and screened this Hsp104 library against a-syn, FUS, or TDP-43 toxicity (Johnson et al., 2008; Outeiro and Lindquist, 2003; Sun et al., 2011) . We employed Dhsp104 yeast, as deletion of Hsp104 does not affect a-syn, FUS, or TDP-43 toxicity (Johnson et al., 2008; Ju et al., 2011) . We identified several Hsp104 variants that potently rescued a-syn, FUS, and TDP-43 toxicity, whereas Hsp104 WT was ineffective ( Figure 1B ). Potentiated Hsp104 variants had a missense mutation in helix 1 (Hsp104
V426L
) or in the distal loop between helix 1 and 2 (Hsp104 A437W ) or in helix 3 (Hsp104 A503V or Hsp104 Y507C )
( Figures 1A and 1B) . Unexpectedly, we uncovered an enhanced variant with a missense mutation in the NBD1 small domain (Hsp104 N539K ) ( Figures 1A and 1B) . Thus, the MD or small domain of NBD1 can be mutated to potentiate Hsp104 activity against a-syn, FUS, and TDP-43. Two potentiating mutations, A503V and Y507C, lie in MD helix 3. Thus, we performed a valine scan of helix 3 (residues 498-507) in search of additional enhanced variants ( Figures 1C and 1D ). Most helix-3 valine substitutions behaved like Hsp104 WT ( Figure 1C ). However, Hsp104
D504V suppressed a-syn, FUS, and TDP-43 toxicity ( Figure 1C Figure S1A available online). Likewise, additional substitutions at D504 (to C), V426 (to G), or N539 (to E, D, G, or K) yielded potentiated Hsp104 variants against FUS toxicity (Figures S1A and S1B) . Thus, diverse mutations at specific positions in the MD enhance Hsp104 activity.
Hsp104
A503X Variants Suppress TDP-43 Toxicity and Promote Its Proper Localization Hsp104 A503V was among the strongest suppressors of a-syn, FUS, and TDP-43 toxicity, and so we explored this position further and mutated A503 to all amino acids. None of these Hsp104 variants were toxic to yeast when overexpressed at 30 C ( Figure S2 ). Mutation of A503 to V, S, or C suppressed TDP-43 toxicity; Hsp104 A503C most strongly suppressed TDP-43 toxicity, followed by Hsp104 A503S and Hsp104 A503V (Figures 2A, 2B, and S3A) . Surprisingly, mutation of A503 to nearly any residue suppressed TDP-43 toxicity, whereas Hsp104 A503P enhanced toxicity (Figures 2A and S3A ). Indeed, we could now mutate the conserved pore loop Y residues (Y257 and Y662) to F (Hsp104 A503V-DPLF ) and retain suppression of TDP-43 toxicity ( Figure 2A ). Rescue of TDP-43 toxicity was not due to lower levels of TDP-43, which were roughly equal across strains (Figure 2C) . Likewise, rescue could not be explained by higher Hsp104 expression. Hsp104 variants were expressed at slightly lower levels than Hsp104 WT ( Figure 2C ). Quantitative immunoblot revealed that Hsp104 hexamer:TDP-43 ratios were 1:1.31 for Hsp104 WT and 1:2.20 for Hsp104
A503V
. Hsp70 and Hsp26 levels were also similar for all strains, indicating that Hsp104 variants do not induce a heat shock response (HSR; Figure 2C ). Hsp104 A503V expression from the native Hsp104 promoter (which is weaker than the galactose promoter)
suppressed TDP-43 toxicity ( Figures S4A and S4B (Figure 2D) . Thus, neither the UPR nor autophagy is needed for enhanced Hsp104 variants to rescue TDP-43 toxicity. TDP-43 normally shuttles between the nucleus and cytoplasm. However, in ALS, TDP-43 is usually depleted from the nucleus and aggregated in the cytoplasm of degenerating motor neurons (Robberecht and Philips, 2013) . Indeed, cytoplasmic TDP-43 aggregates persist upon Hsp104
WT overexpression (Figure 2E) . By contrast, Hsp104 A503V eliminated cytoplasmic TDP-43 aggregates and 46% of cells had nuclear TDP-43 localization ( Figure 2E ). Accordingly, Hsp104 A503V reduced the amount of insoluble TDP-43 by 57%, whereas Hsp104 WT was ineffective ( Figure 2F ). Thus, Hsp104
A503V eliminates TDP-43 aggregation and toxicity and restores TDP-43 to the nucleus. These phenotypes are a therapeutic goal for ALS and other TDP-43 proteinopathies. Several suppressors of TDP-43 toxicity have been isolated in yeast, but none clear cytoplasmic TDP-43 aggregates (Sun et al., 2011) . Thus, our enhanced Hsp104 variants are the first (to our knowledge) genetic suppressors that eradicate TDP-43 aggregates and restore TDP-43 to the nucleus. (Ju et al., 2011; Robberecht and Philips, 2013; Sun et al., 2011 Hsp26 in a HSR, or higher Hsp104 levels ( Figure 3C ). Indeed, quantitative immunoblot revealed that Hsp104 hexamer:FUS ratios were 1:5.13 for Hsp104 WT and 1:3.25 for Hsp104 A503V .
Even low Hsp104 A503V levels expressed from the natural , and Hsp104 A503V-DPLF occurred in Dire1 strains and Datg8 strains ( Figure 3D ). Thus, the UPR and autophagy are not required for potentiated Hsp104 variants to suppress FUS toxicity. Hsp104 A503V eliminated FUS aggregates, whereas Hsp104 WT had no effect ( Figure 3E ). In contrast to TDP-43, FUS was now diffuse in the cytoplasm ( Figure 3E ) because the yeast nuclear transport machinery fails to decode the FUS PY-NLS (Ju et al., 2011) . Hsp104 A503V reduced the amount of insoluble FUS by 49%, whereas Hsp104 WT was ineffective ( Figure 3F ). Genome-wide overexpression screens have yielded several suppressors of FUS toxicity in yeast, but none that solubilize FUS inclusions (Ju et al., 2011; Sun et al., 2011) . Thus, potentiated Hsp104 variants are the first (to our knowledge) genetic suppressors that eradicate FUS aggregates.
Hsp104
A503X Variants Suppress a-Syn Toxicity and Promote Its Proper Localization Next, we tested Hsp104 A503X variants against a-syn toxicity in yeast. a-Syn is a lipid-binding protein that localizes to the plasma membrane but forms cytoplasmic inclusions in degenerating dopaminergic neurons in PD and in yeast (Cushman et al., 2010; Outeiro and Lindquist, 2003) . Nearly all Hsp104 A503X variants suppressed a-syn toxicity except Hsp104 A503P , which had no effect (Figures 4A, 4B, and S3C ) could not be explained by lower a-syn levels, induction of Hsp70 or Hsp26 in a HSR, or higher Hsp104 levels ( Figure 4C ). Quantitative immunoblot indicated that the Hsp104 hexamer:a-syn ratios were 1:2.43 for Hsp104 WT and 1:2.84
for Hsp104
A503V
. Expression of Hsp104 A503V from the Hsp104 promoter suppressed a-syn toxicity, whereas Hsp104
WT had no effect ( Figures S4E and S4F , and Hsp104
A503V-DPLF rescued a-syn toxicity in Dire1 and Datg8 strains ( Figure 4D ). Thus, the UPR and autophagy are not required for rescue. Hsp104 A503V eliminated cytoplasmic a-syn inclusions and restored plasma membrane a-syn localization, whereas Hsp104 WT had no effect ( Figure 4E ). Indeed, Hsp104 A503V reduced the amount of insoluble a-syn by 66%, whereas Hsp104 WT increased it by 33.9% ( Figure 4F ). Thus, potentiated
Hsp104 variants eradicate a-syn inclusions and restore a-syn localization.
Potentiated Hsp104 Variants Prevent Neurodegeneration in a C. elegans PD Model
To test potentiated Hsp104 variants in a metazoan nervous system, we used a transgenic C. elegans PD model, which has illuminated mechanisms and modifiers of a-syn-induced neurodegeneration (Cao et al., 2005; Cooper et al., 2006; Tardiff et al., 2013) . We selected Hsp104 A503S and Hsp104 A503V-DPLF to study in this context, which displayed strong (Hsp104
A503S
) and moderate (Hsp104 A503V-DPLF ) rescue of a-syn toxicity ( Figure 4A ).
We focused on these variants because unlike Hsp104 A503V they conferred greater than WT levels of thermotolerance and were less toxic to yeast at 37 C when expressed from the galactose promoter ( Figures S5A and S5B) .
The dopamine transporter (dat-1) gene promoter was used to direct expression of Hsp104 variants and a-syn to dopaminergic (DA) neurons. Expression of a-syn alone resulted in 16% of animals with normal numbers of DA neurons after 7 days and 8% of animals after 10 days compared to controls ( Figures 5A-5C ). Coexpression of Hsp104
WT or an ATPasedead, substrate binding-deficient Hsp104 DPLA-DWB (which bears the ''double pore loop'' and ''double Walker B'' mutations: Y257A:E285Q:Y662A:E687Q) did not rescue neurodegeneration ( Figures 5A and 5B) . C. elegans expressing Hsp104 A503S or Hsp104 A503V-DPLF displayed significant protection (30.5% and 34% normal worms, respectively) compared to the null Hsp104 variant or a-syn alone at day 7 ( Figure 5A ). This trend continued at day 10 ( Figure 5B ), when Hsp104 A503S -expressing (21%) and Hsp104
A503V-DPLF -expressing (24%) worms had significantly more normal DA neurons compared to a-syn alone (7.8%), Hsp104 DPLA-DWB (10%), or Hsp104 WT (11%). Hsp104 variants did not alter a-syn mRNA levels ( Figure S5C) Figures 6B and 6C) . Typically, in the absence of Hsc70 and Hdj2, potentiated Hsp104 variants were 3-to 9-fold more active than Hsp104
WT plus Hsc70
and Hdj2 ( Figure 6B ). The only exception was Hsp104 D498V , which in the absence of Hsc70 and Hdj2 was still as active as Hsp104
WT plus Hsc70 and Hdj2 ( Figure 6B ). Hsp104 WT was most active in the presence of Ssa1, Ydj1, and the Hsp110, Sse1 ( Figure 6C ) (Shorter, 2011 A503S , and Hsp104 A503V-DPLF activity in the absence of Ssa1, Ydj1, and Sse1 ( Figure 6C ). In the presence of Ssa1, Ydj1, and Sse1, the luciferase reactivation activity of Hsp104 A503V , Hsp104 A503S , and Hsp104 A503V-DPLF was 7-to 8-fold higher than Hsp104 WT ( Figure 6C ). Potentiated Hsp104 variants are highly active without Hsp70 and Hsp40 ( Figures  6B and 6C) . Thus, absolute dependence on Hsp70 and Hsp40 hinders Hsp104 from rescuing a-syn, FUS, and TDP-43 toxicity.
Independence from Hsp70 and Hsp40 is promising for applying Hsp104 variants to reverse protein misfolding in diverse systems, such as purification of aggregation-prone recombinant proteins from E. coli where DnaK incompatibility is an issue (DeSantis and Shorter, 2012). 
Potentiated Hsp104 Variants Are Enhanced Unfoldases
Next, we established that enhanced Hsp104 variants had enhanced unfoldase activity using a RepA 1-70 -GFP substrate (Doyle et al., 2007) . To assess RepA 1-70 -GFP unfolding in the absence of spontaneous refolding, we added GroEL trap , which captures unfolded proteins and prevents refolding (Weber-Ban et al., 1999) . Hsp104
WT unfolds RepA 1-70 -GFP, but only in the presence of a permissive ratio of ATP and ATPgS (Doyle et al., 2007) (Figures 6G and 6H ). Thus, with ATP alone, Hsp104 WT did not unfold RepA 1-70 -GFP ( Figure 6G ). By contrast, Hsp104 A503X variants rapidly unfolded RepA 1-70 -GFP in the presence of ATP ( Figure 6G ). Hsp104
WT unfolded RepA 1-70 -GFP in the presence of an ATP:ATPgS (3:1) mixture. By contrast, ATP: ATPgS slightly inhibited Hsp104 A503V unfoldase activity, but even here, Hsp104 A503V unfolded RepA 1-70 -GFP more rapidly than Hsp104 WT ( Figure 6G ). Hsp104 A503X variants had very similar unfoldase kinetics ( Figure 6G ). By contrast, Hsp104 D498V , Hsp104 D504C , and Hsp104 A503V-DPLF were slightly slower unfoldases than Hsp104 A503V , whereas Hsp104 Y507C was slightly faster ( Figure 6H ). These differences could reflect changes in substrate recognition or turnover or both. Regardless, potentiated Hsp104 variants are enhanced unfoldases that are intrinsically primed to unfold substrates and do not have to wait for regulatory events (mimicked here by ATPgS addition). et al., 2012) . By contrast, the luciferase disaggregase activity of Hsp104 A503V was stimulated by Hsp104 A503V-DWB subunits ( Figure 6J ). Fluorescence resonance energy transfer (FRET) studies confirmed that Hsp104 A503V-DWB subunits incorporated into Hsp104 A503V hexamers. The FRET efficiency was 0.36 (compared to 0.38 for mixing Hsp104 WT with Hsp104 DWB ; DeSantis et al., 2012) using the conditions employed for luciferase reactivation. In high-salt buffer (1 M NaCl), hexamerization is inhibited and FRET efficiency decreased to 0.24. At a higher Hsp104 concentration (1 mM), which favors hexamerization, FRET efficiency increased to 0.43. We could model the stimulatory effect of Hsp104 A503V-DWB subunits if we imposed rules whereby an Hsp104 A503V-DWB subunit stimulates activity of an adjacent Hsp104 A503V subunit 2-fold ( Figure 6J ). (Johnson et al., 2009; Sun et al., 2011) . Hsp104 WT was unable to resolve TDP-43 aggregates and slightly enhanced TDP-43 aggregation in the absence of Ssa1, Ydj1, and Sse1 ( Figure 7D ). By contrast, Hsp104 A503V and Hsp104 A503S partially resolved TDP-43 aggregates in the absence of Ssa1, Ydj1, and Sse1 ( Figure 7D Figure 7F ). Hsp104 A503V and Hsp104 A503S effectively disaggregated FUS in the presence of Ssa1, Ydj1, and Sse1, whereas Hsp104 WT was ineffective ( Figure 7F ). Indeed, Hsp104
A503V
and Hsp104 A503S eradicated FUS fibrils ( Figure 7G ). Thus, We have identified the MD as a key region governing Hsp104 function. It is perplexing and unprecedented that missense mutations to nearly any residue at specific and disparate positions (e.g., A503, Y507) confer a therapeutic gain of function. Potentiation stems from loss of amino acid identity rather than specific mutation. Thus, Hsp104 activity is likely tightly constrained but can be unleashed by subtle changes to side chains at specific positions. These constraints are too tight for Hsp104
WT to counter TDP-43, FUS, and a-syn aggregation and toxicity under the conditions employed in our experiments. Thus, we reveal a surprising inimical deficit in existing disaggregase functionality. We suggest that the MD functions as a capacitor braced to unleash Hsp104 activity. Missense mutations at specific positions in MD helix 1, 2, or 3 or the small domain of NBD1 (immediately C terminal to the MD) likely destabilize autoinhibitory interactions that dampen Hsp104 activity or induce conformational changes that mimic or aid in an allosteric activation step. Potentiating mutations obviate any absolute requirement for Hsp70 and enhance Hsp104 ATPase activity, substrate translocation speed, unfoldase activity, and amyloid disaggregase activity. Additionally, Hsp104 A503V hexamers display enhanced plasticity and are more resistant to defective subunits than Hsp104
WT . Thus, enhanced variants possess a more robust disaggregase activity that is desensitized to inhibition. Irrespective of the mechanism of activation, we have established that seemingly minor structural modulation of a disaggregase can suppress a constellation of otherwise intractable proteotoxicities in vivo. We are unaware of any precedent for attaining such a wide-reaching set of gain of therapeutic functions via such minor changes in primary sequence, e.g., by removing a single methyl group (A503G) or by adding a single methylene bridge (V426L). Further engineering to develop enhanced variants that specifically target single proteins (e.g., disaggregate FUS, but not (legend continued on next page) TDP-43) will prove valuable to minimize any off-target effects. Hsp104 could be potentiated against any protein, which might find key applications in purification of troublesome recombinant proteins. Irrespective of the feasibility of introducing Hsp104 as a therapeutic, our work suggests that protein aggregates are not intractable and that general neuroprotection via altered proteostasis is achievable. Ultimately, we envision introducing potentiated Hsp104 variants in short transient bursts to restore natural proteostasis. In this way, long-term expression of an exogenous protein is avoided. Reactivation of disease-associated proteins to their nonpathogenic states suggests that Hsp104 variants and other agents that achieve this goal may be highly promising for halting and reversing neurodegenerative disease. Nonetheless, caution is needed and many barriers must be breached to translate Hsp104 variants into disruptive technologies and potential therapeutics.
EXPERIMENTAL PROCEDURES Yeast Strains and Media
Yeast were WT W303a or the isogenic W303aDhsp104 strain. Dire1 and Datg8 were in BY4741. Standard methods were used for transformation and spotting. See the Extended Experimental Procedures for more information.
Library Construction and Screening
The pore loop variant library was constructed via QuikChange mutagenesis (Agilent) and DNA shuffling to obtain randomly combined residues at positions Y257 and Y662. The MD variant library was constructed using GeneMorph II EZClone Domain Mutagenesis kit (Agilent) with modifications. Libraries were transformed into yeast harboring pAG303GAL-TDP-43, pAG303GAL-FUS, or pAG303GAL-a-syn. Yeast were grown overnight in raffinose-containing media and plated on galactose-containing media for selection. Select colonies were sequenced by colony PCR. Isolated Hsp104 variants were cloned independently and transformed into yeast to ensure they suppressed toxicity. See the Extended Experimental Procedures for more information.
Hsp104 Variant Toxicity and Thermotolerance
W303aDhsp104 yeast were transformed with the indicated 416GAL-Hsp104 plasmid. Cultures were grown in synthetic raffinose medium to A 600nm = 2.0, spotted onto SD-Ura or SGal-Ura, and incubated at 30 C or 37 C for 48-72 hr. For thermotolerance, yeast were grown to saturation in synthetic raffinose media and diluted to A 600nm = 0.3 in galactose-containing media. After 4 hr at 30 C, cells were heat shocked at 50 C for 0-30 min, cooled for 2 min on ice, serially diluted, and spotted on synthetic dropout media containing galactose. Plates were incubated at 30 C for 48-72 hr.
Sedimentation Analysis
Yeast were induced in galactose-containing medium for 5 hr (TDP-43 and FUS) or 8 hr (a-syn). Cells were lysed, separated into soluble and insoluble fractions by sedimentation, and processed for quantitative immunoblot. See the Extended Experimental Procedures for more information. 
TDP-43 and FUS Disaggregation
To generate TDP-43 and FUS aggregates, GST-TEV-TDP-43 (6 mM) or GST-TEV-FUS (6 mM) was incubated with TEV protease in 50 mM Tris-HCl (pH 7.4), 50 mM KCl, 5 mM MgCl 2 , 0.2 M trehalose, and 20 mM glutathione. FUS was aggregated for 90 min at 25 C without agitation, by which time all the FUS had aggregated (Sun et al., 2011) . TDP-43 was aggregated for 4 hr at 25 C with agitation, by which time all the TDP-43 had aggregated (Johnson et al., 2009 ). TDP-43 or FUS aggregates (3 mM monomer) were incubated for 1 hr at 30 C with Hsp104 WT , Hsp104 A503V , or Hsp104 A503S (1 mM) plus or minus Ssa1 (1 mM), Ydj1 (0.44 mM), and Sse1 (0.26 mM) plus ATP (10 mM) and ARS (20 mM creatine phosphate and 0.5 mM creatine kinase). Disaggregation was assessed via turbidity (absorbance at 395 nm) and EM (Johnson et al., 2009; Sun et al., 2011) . 
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